Obesity最新文献

{"title":"Musculoskeletal Outcomes of Glucagon-Like Peptide-1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults","authors":"Jie-Syuan Wu,&nbsp;Lee-Yuan Lin,&nbsp;Jia-Wei Sun,&nbsp;Wei-Ting Yu,&nbsp;Fara Silvia Yuliani,&nbsp;Shyh-Hsiang Lin","doi":"10.1002/oby.70218","DOIUrl":"10.1002/oby.70218","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to evaluate the association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective cohort study included deidentified TriNetX data on ≥ 50-year-old nondiabetic adults with obesity. After 1:1 propensity score matching on demographic, clinical, and laboratory covariates, 18,062 GLP-1 RA users were compared with non-GLP-1 medication users. The primary outcome was incident osteoporosis; secondary outcomes included major osteoporotic fractures, cervical and thoracolumbar disc disorders, and osteoarthritis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>GLP-1 RA use was associated with lower risks of osteoporosis (relative risk [RR] 0.48; 95% CI, 0.43–0.52; number needed to treat [NNT] = 28), major osteoporotic fractures (RR 0.15; 95% CI, 0.11–0.22; NNT = 88), cervical disc degeneration (RR 0.34; 95% CI, 0.28–0.41; NNT = 63), thoracolumbar disc disease (RR 0.36; 95% CI, 0.33–0.40; NNT = 20), and osteoarthritis (RR 0.45; 95% CI, 0.43–0.48; NNT = 9). Protective associations were consistent across age, sex, BMI, and drug subtype subgroups and remained robust in sensitivity analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>GLP-1 RA use was associated with favorable musculoskeletal outcomes, including lower risks of osteoporosis and fractures, in nondiabetic adults with obesity compared with other obesity medications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S2","pages":"119-131"},"PeriodicalIF":4.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70218","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148145965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unanticipated Effects of GLP-1 Receptor Agonists: A Net Positive","authors":"Adam H. Gilden,&nbsp;Steven B. Heymsfield","doi":"10.1002/oby.70288","DOIUrl":"10.1002/oby.70288","url":null,"abstract":"","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S2","pages":"7-8"},"PeriodicalIF":4.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148633347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-Like Peptide-1 Receptor Agonists: Considerations for Treating Preconception Obesity","authors":"Lauren T. Berube,&nbsp;Michael A. Weintraub,&nbsp;Hedda L. Boege,&nbsp;Cheryl R. Stein,&nbsp;Andrea L. Deierlein","doi":"10.1002/oby.70210","DOIUrl":"10.1002/oby.70210","url":null,"abstract":"","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S2","pages":"13-15"},"PeriodicalIF":4.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effects of Incretin Mimetic Therapies on Muscle and Bone Health in Older Adults: A Narrative Review","authors":"Joseph M. Saavedra,&nbsp;Alissa S. Chen,&nbsp;Kathryn N. Porter Starr,&nbsp;John A. Batsis","doi":"10.1002/oby.70203","DOIUrl":"10.1002/oby.70203","url":null,"abstract":"<div>\u0000 \u0000 <p>Incretin mimetics are increasingly prescribed for the treatment of overweight and obesity, resulting not only in significant weight reduction but also co-occurring improvements in cardiovascular health and quality of life. Incretin mimetic use among older adults is expected to increase as the population ages into obesity. However, older adults experience accelerated losses in skeletal muscle mass and bone mineral density, and it remains unclear how incretin mimetics affect these processes. This review outlines the age-associated changes in muscle and bone and explores current evidence reporting the effects/associations of incretin mimetics on these tissues, as well as on physical function and fragility fracture risk. We identified several incretin mimetic weight reduction trials that demonstrated significant losses in lean soft tissue (<i>n</i> = 6 studies) and/or indices of bone (<i>n</i> = 3); however, the clinical significance of these decrements on physical function and/or fragility fracture remains unclear. Considering a rising trend in the prescription of incretin mimetics to treat obesity in older adulthood, a more robust characterization of the impact of these medications on lean soft tissue, physical function, and fragility fracture is needed to support future clinical decision-making in older adults with overweight/obesity.</p>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S2","pages":"36-50"},"PeriodicalIF":4.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148431857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 Receptor Agonists and Substance Use Disorders in Older Adults With Type 2 Diabetes: A Target Trial Emulation","authors":"Hao Dai,&nbsp;Rotana M. Radwan,&nbsp;Grant D. Scheiffele,&nbsp;Huilin Tang,&nbsp;Amy Sheer,&nbsp;Hsin-Yueh Lin,&nbsp;Pengyue Zhang,&nbsp;Darlene Adirika,&nbsp;Kate Luong,&nbsp;Jiang Bian,&nbsp;Jingchuan Guo","doi":"10.1002/oby.70024","DOIUrl":"10.1002/oby.70024","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for type 2 diabetes (T2D) and obesity, may modulate reward pathways and reduce substance-related behaviors. This study assessed the association between GLP-1RA use and substance use-related hospitalization in older adults with coexisting T2D and substance use disorders (SUD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective cohort study using 2016–2020 Medicare data compared GLP-1RA initiators with new users of SGLT2 inhibitors (SGLT2is) or DPP-4 inhibitors (DPP4is) among adults aged ≥ 65. The primary outcome was hospitalization for any SUD; secondary outcomes included hospitalizations for alcohol use disorder (AUD) and opioid use disorder (OUD). Propensity score 1:1 matching and Cox proportional hazards models were used under an intention-to-treat approach.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the GLP-1RA versus DPP4i cohort (<i>n</i> = 4920), GLP-1RA users had a lower risk of SUD hospitalization (HR 0.76; 95% CI, 0.67–0.86) and OUD hospitalization (HR 0.64; 95% CI, 0.43–0.96), with a nonsignificant trend for AUD (HR 0.76; 95% CI, 0.53–1.08). No significant differences were observed compared to SGLT2is (<i>n</i> = 4620).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Among older adults with T2D, GLP-1RA use was associated with reduced SUD-related hospitalization versus DPP4i use, suggesting potential repurposing for SUD management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S2","pages":"88-100"},"PeriodicalIF":4.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency","authors":"Ellina Lytvyak,&nbsp;Arshdeep Rattol,&nbsp;Eduardo Grunvald","doi":"10.1002/oby.70213","DOIUrl":"10.1002/oby.70213","url":null,"abstract":"<p>Setmelanotide, a melanocortin 4 receptor (MC4R) agonist, is a promising pharmacological treatment option for people with rare monogenic obesity conditions affecting the leptin-melanocortin signaling pathway, including proprotein convertase subtilisin/kexin type 1 (<i>PCSK1</i>) gene mutations. It has been studied in people with homozygous mutations causing a complete deficiency of <i>PCSK1</i>. We report the first case of a 40-year-old female with a heterozygous <i>PCSK1</i> N221D (c.661 A&gt;G) variant mutation leading to severe early-onset treatment-resistant obesity with previous suboptimal response to bariatric surgery and conventional obesity medications, who achieved a total weight loss of 11.8% with setmelanotide treatment over the course of 3 months. Although her mutation confers a loss of 10% to 30% enzymatic function in in vitro studies, setmelanotide was highly effective in treating her obesity. It is also the first reported case of a cutaneous adverse effect of setmelanotide in the form of severe skin hyperpigmentation in a patient with a pathogenic <i>PCSK1</i> variant. This case underscores the effectiveness and safety of setmelanotide in a heterozygous <i>PCSK1</i> mutation.</p>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S2","pages":"70-74"},"PeriodicalIF":4.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70213","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147825290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Evolving Real-World Adverse Events of GLP-1RAs Using FDA Adverse Event Reporting System (FAERS)","authors":"David Stone,&nbsp;Mary Playdon,&nbsp;Stephen D. Hursting,&nbsp;Aik Choon Tan","doi":"10.1002/oby.70176","DOIUrl":"10.1002/oby.70176","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon-like peptide-1 receptor agonists (GLP-1RAs) using the US FDA Adverse Event Reporting System (FAERS). Emphasis was placed on emerging safety concerns in context-specific use.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective analysis of FAERS reports between 2012 and 2025 was conducted. Five commonly prescribed FDA-approved GLP-1RAs were included. Disproportionality analyses were applied to detect AE signals. Subgroup analyses evaluated associations by indication, GLP-1RAs compared to other drugs, and AEs specific to individual GLP-1RAs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From over 18 million FAERS reports, 137,451 involved GLP-1RAs. The most frequent AEs were gastrointestinal, nutritional and metabolic, and psychiatric disorders, occurring at higher rates compared to other drugs. In diabetes use, GLP-1RAs were associated with retinopathy, hearing loss, and cataracts. In contrast, when prescribed for weight management/obesity, nutritional, metabolic, and psychiatric AEs predominated. We also developed an open-access portal for AE exploration, available at http://glp1.tanlab.org.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <div>GLP-1RAs are linked to a broad range of AEs across indications. These findings stress the need for careful clinical monitoring and long-term safety evaluation. This study also illustrates how real-world evidence can inform safety communications, as well as hypothesis generation for research on next-generation GLP-1RAs.\u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S2","pages":"101-108"},"PeriodicalIF":4.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70176","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147380263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Use in Elderly People With Obesity—A Meta-Analysis","authors":"Inês Rego de Figueiredo,&nbsp;Filipa Sofia Simas,&nbsp;Angela Ghiletchi,&nbsp;João Oliveira Torres,&nbsp;José Silva-Nunes","doi":"10.1002/oby.70098","DOIUrl":"10.1002/oby.70098","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This meta-analysis evaluates the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) for the treatment of older adults with obesity compared to younger individuals.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381). PubMed, Embase, and Scopus were searched until May 17, 2025, for randomized controlled trials and observational studies assessing GLP-1 RA in adults ≥ 65 years with obesity with or without type 2 diabetes. Random effects meta-analyses calculated the log odds ratios (LOR) for dichotomous outcomes and the mean differences (MD) for continuous outcomes, with equivalence testing via two one-sided tests (TOST) and meta-regression for baseline adjustments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Five studies involving 1229 participants were included. No significant difference in serious adverse events was found between older and younger adults (pooled LOR: 0.06, <i>p</i> = 0.9). Older adults had a trend toward lower frequency of nausea (LOR: −0.44, <i>p</i> = 0.06) but higher incidence of constipation (LOR: 0.72, <i>p</i> = 0.02) and hypoglycemia (LOR: 0.97, <i>p</i> &lt; 0.001). Efficacy in metabolic and weight control was comparable. Additionally, one study suggested that liraglutide could reduce fat mass without worsening sarcopenia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>GLP-1 RA therapy seems to be safe and effective in older adults with obesity, achieving similar effects on weight loss and glycemic control as in younger individuals.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S2","pages":"25-35"},"PeriodicalIF":4.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70098","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146121566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-Like Peptide-1 Receptor Agonist-Based Agents and Body Composition: Filling More Gaps","authors":"Robert L. Dubin,&nbsp;Tierra N. Sanders,&nbsp;Hunter M. Schwab,&nbsp;Steven B. Heymsfield,&nbsp;Frank L. Greenway","doi":"10.1002/oby.70212","DOIUrl":"10.1002/oby.70212","url":null,"abstract":"<p>The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight-based outcomes but by changes in body composition. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can be quantified by changes in percent fat/fat-free mass as a total of body weight. The amount of weight that is lost as % fat-free mass (% FFML) with diet-induced weight loss is ~25% but is extremely variable. Our aim was to provide an update to our previous report assessing changes in body composition using GLP-1 RA-based agents. In our updated review of 40 DXA-based reports, we found the mean (SD) % FFML was 29.1% (19.0%). Similar to our previous report, we found that the changes in body composition using these agents remain in the upper range of expected % FFML using other nonsurgical interventions for obesity. Functional measures of strength and performance and assessing body composition effects of future GLP-1-based agents are needed to understand the continued gaps that exist in determining the impact these treatments have, particularly in high-risk populations.</p>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S2","pages":"51-63"},"PeriodicalIF":4.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70212","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148407622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective","authors":"Fernanda Baeza Scagliusi,&nbsp;Bruno Gualano,&nbsp;Pernille Andreassen,&nbsp;Cindi SturtzSreetharan,&nbsp;Sissel Due Jensen,&nbsp;Alexandra Brewis","doi":"10.1002/oby.70069","DOIUrl":"10.1002/oby.70069","url":null,"abstract":"<p>The off-label use of glucagon-like peptide-1 receptor agonists (GLP-1ra) among people without obesity and/or diabetes is rapidly expanding, despite a lack of clinical justification or safety data in this population. This Perspective explores the sociomedical dimensions of this trend, highlighting key research gaps and emerging hypotheses around the off-label use of GLP-1ra to an individual goal of slimness rather than health. We propose that off-label GLP-1ra use by people with normative or mildly elevated weight reveals deeper tensions between scientific progress, stigma, and cultural ideals of the body. Understanding this phenomenon requires moving beyond biomedical efficacy to interrogate the psychological, behavioral, and sociopolitical implications of pharmacological thinness. Cross-cultural and intersectional approaches from the social sciences are key to understanding this emergent phenomenon.</p>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S2","pages":"9-12"},"PeriodicalIF":4.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70069","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145497820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}